Luke E. Gaughan

Framlington Place
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

A xeno-free human iPSC-derived prostate organoid platform for multilineage differentiation and genetic manipulation.

A xeno-free human iPSC-derived prostate organoid platform for multilineage differentiation and genetic manipulation.

Journal: Cell reports methods

Published: May 05, 2026

Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation.

Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation.

Journal: RSC medicinal chemistry

Published: February 13, 2026

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 01, 2025

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Journal: The Journal of clinical investigation

Published: July 23, 2025

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

Journal: The Journal of clinical investigation

Published: July 22, 2025

Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness.

Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness.

Journal: Molecular cancer therapeutics

Published: May 29, 2025

Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.

Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.

Journal: Molecular cancer research : MCR

Published: March 15, 2024

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.

Journal: Nature communications

Published: January 09, 2024

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

Journal: Communications biology

Published: April 11, 2023

Release of Histone H3K4-reading transcription factors from chromosomes in mitosis is independent of adjacent H3 phosphorylation.

Release of Histone H3K4-reading transcription factors from chromosomes in mitosis is independent of adjacent H3 phosphorylation.

Journal: Nature communications

Published: April 05, 2023

Engineering prostate cancer in vitro: what does it take?

Engineering prostate cancer in vitro: what does it take?

Journal: Oncogene

Published: March 30, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026